We use cookies to make your experience better. To comply with the new privacy directive, we need to ask for your consent to set the cookies. Learn more

Myopharm is developing a novel mechanism of action, combination drug candidate to address the large unmet need in type two diabetes treatment failures and to address progressive beta-cell loss through reducing proinflammatory mediators within the PGE2 signaling pathway.

Latest News
VIEW ALL NEWS

Myopharm is an IND stage biotechnology company focused on developing first in class, novel therapeutics for the treatment and prevention of Type 2 diabetes. Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric dual combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics.

In addition to this, Myopharm has a rapidly growing portfolio of clinically validated medical foods indicated in the Type 2 diabetes, Insulin Resistance and Prediabetes space and an Australian Food Standards compliant VLED weight loss food product.

We were incredibly honoured that the American Diabetes Association(ADA) featured Myopharm Limited in the Thought Leadership Film Series, a part of ADA's 84th Scientific Sessions program in June 2024, starting today.

In the invitation letter, it was written: We are interested in profiling Myopharm's pioneering work to revolutionize the treatment landscape for Type 2 diabetes, including your work on TriGlytza™. Despite the extensive array of treatments currently available, none specifically address the root cause of the disease with a focus on preserving and enhancing the function of pancreatic beta cells, a critical unmet need in the diabetic community. Given that your work introduces a novel 'Beta-cell centric' therapeutic strategy, aiming to maintain or restore beta-cell function while mitigating insulin resistance, we believe your work has the potential to make an incredibly valuable addition.

Watch the video in English here

TriGlytza™ is a beta-cell centric dual combination drug that proposes to mitigate progressive beta-cell deterioration by reducing levels of pro-inflammatory mediators.

Reports

View All Reports

Latest Announcements

View All Announcements

Australian Diabetes Congress 2022 turns the spotlight on the latest breakthroughs

The Australian Diabetes Congress 2022 once again brought to light the effects of diabetes on the health system, but there were positives in the latest breakthroughs in research, education and clinical care.

The national Diabetes Services Scheme (NDSS) recorded 118,800 and over 119,000 new registrants between March 2020–2021 and March 2021–2022 – the highest recorded number of any 12-month period.

National Diabetes Week highlights

It’s a shocking statistic. More than 300 Australians, or one person every five minutes, develops diabetes every day.

Think about that: one person every five minutes.

And the number of diagnoses is multiplying daily. Currently, almost 1.9 million Australians have diabetes and close to 120,000 Australians have developed diabetes in the past year.

The Rising Global Prevelance of Diabetes

As the Covid-19 pandemic dominated the headlines over the past year, the fact that the number of people living with - and dying from - diabetes has continued to rise has gone rather unnoticed.

Quick Links

Contact Us

Myopharm Limited
Levels 1, 2 & 3 60 Martin Place
Sydney
New South Wales
2000
Telephone +61 2 8527 2453
Email: info@myopharm.com

Stay in Touch

Email Alerts

Subscribe to our Email Alerts

Follow Us

Copyright © Myopharm
Site Map Terms & Conditions